HIV AIDS News

Federal health officials Wednesday outlined how they plan to achieve the goal of no new HIV cases in the U.S. by 2030, announced by President Donald Trump in Tuesday evening’s State of the Union address.

A recent review studies from the last decade found no cases of HIV transmission when the HIV-positive partner was on drug "cocktails" that were keeping the virus suppressed.

In a study of gay men who did not have HIV who were given antiviral drugs protectively, the number of new HIV infections fell from 295 cases in the year before the program rollout to 221 cases the year after.

A combination of two HIV-fighting antibodies, given to small group of people with HIV, appears to suppress the virus for a few months even after the person stops taking the drugs. Researchers hope it means could one day people could stop taking daily pills for HIV.

HIV, AIDS, treatment, T cells, monoclonal antibody

More than two-thirds of HIV-associated heart disease occurs in sub-Saharan Africa and Asia Pacific regions, according to the study.

Experimental HIV Vaccine Promising in Early Trial By Robert PreidtHealthDay Reporter FRIDAY, July 6, 2018 (HealthDay News) -- An experimental HIVvaccine was safe and triggered strong immune responses in healthy adults and in monkeys, researchers report.They say it also protected two-thirds of monkeys against an HIV-like virus.Though results of animal studies are not always the same in humans, researchers are encouraged by this early-stage study, which included nearly 400 healthy people. For their next step, they are launching a new vaccine trial that will include 2,600 women in southern Africa who are at risk of HIV infection.The

The vaccine targets a vulnerable site on HIV -- the virus that causes AIDS -- and triggered antibody production in mice, guinea pigs and monkeys, according to researchers with the U.S. National Institute of Allergy and Infectious Diseases (NIAID).

The study found no difference in the risk for premature birth, low birth weight or other serious complications among those who didn't receive TDF and those who got TDF along with emtricitabine and lopinavir/ritonavir.

The new test may be able to detect early evidence of HIV antibodies in saliva as reliably as a blood test, according to the scientists who developed it.

Researchers say a once-a-week, slow-release pill may keep HIV infections under control and help prevent new HIV infections altogether.

Teens who engage in risky behaviors are more likely to have unsafe sex -- and that may put them at increased risk for HIV, the AIDS-causing virus, University of Michigan researchers reported.

The science centers around the use of "chimeric antigen receptor" (CAR) genes. In laboratory work with monkeys, these engineered cells have destroyed HIV-infected cells for more than two years, scientists reported.

A new study warns of a potential return to the "bad old days" when there were no effective drugs to fight HIV, the virus that causes AIDS.

The average time between HIV infection and diagnosis was three years in 2015, seven months earlier than it had been in 2011, according to researchers from the U.S. Centers for Disease Control and Prevention.

Combination strategy fully protects lab monkeys, studies find

Small study found Truvada worked when taken daily, but some strayed from regimen

Study of gay couples duplicates findings of earlier research

Boy's HIV In Remission Years After Treatment Ended

If findings replicated, a shot every month or two could replace daily pills, scientists say

Infection rate could be as low as 12,000 people a year by 2025, researchers report

Still small, but persistent gaps for some groups with HIV, global health expert says

About 10,000 Americans were infected at birth, and many are now young adults with medical issues, study finds

Case numbers fell steeply between 2002 and 2013, but even more could be done, experts say

Better treatments may translate into complacency, HIV experts say